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ABSTRACT Cellular antiviral proteins interfere with distinct steps of replication cycles of
viruses. The galectin 3 binding protein (LGALS3BP, also known as 90K) was previously
shown to lower the infectivity of nascent human immunodeﬁciency virus type 1 (HIV-1)
virions when expressed in virus-producing cells. This antiviral effect was accompanied by
impaired gp160Env processing and reduced viral incorporation of mature Env glycopro-
teins. Here, we examined the ability of 90K orthologs from primate species to reduce
the particle infectivity of distinct lentiviruses. We show that 90K’s ability to diminish the
infectivity of lentiviral particles is conserved within primate species, with the notable ex-
ception of 90K from rhesus macaque. Comparison of active and inactive 90K orthologs
and variants uncovered the fact that inhibition of processing of the HIV-1 Env precursor
and reduction of cell surface expression of HIV-1 Env gp120 are required, but not sufﬁ-
cient, for 90K-mediated antiviral activity. Rather, 90K-mediated reduction of virion-
associated gp120 coincided with antiviral activity, suggesting that 90K impairs the incor-
poration of HIV-1 Env into budding virions. We show that a single “humanizing” amino
acid exchange in the BTB (broad-complex, tramtrack, and bric-à-brac)/POZ (poxvirus and
zinc ﬁnger) domain is sufﬁcient to fully rescue the antiviral activity of a shortened ver-
sion of rhesus macaque 90K, but not that of the full-length protein. Comparison of the
X-ray structures of the BTB/POZ domains of 90K from rhesus macaques and humans
point toward a slightly larger hydrophobic patch at the surface of the rhesus macaque
BTB domain that may modulate a direct interaction with either a second 90K domain or
a different protein.
IMPORTANCE The cellular 90K protein has been shown to diminish the infectivity of
nascent HIV-1 particles. When produced in 90K-expressing cells, particles bear
smaller amounts of the HIV-1 Env glycoprotein, which is essential for attaching to
and entering new target cells in the subsequent infection round. However, whether
the antiviral function of 90K is conserved across primates is unknown. Here, we
found that 90K orthologs from most primate species, but, surprisingly, not from rhe-
sus macaques, inhibit HIV-1. The introduction of a single amino acid exchange into a
short version of the rhesus macaque 90K protein, consisting of the two intermediate
domains of 90K, resulted in full restoration of antiviral activity. Structural elucidation
of the respective domain suggests that the absence of antiviral activity in the rhesus
macaque factor may be linked to a subtle change in protein-protein interaction.
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Mammalian cells express an arsenal of genes which encode antiviral proteins. Theexpression of most, but not all, of them is upregulated by type I interferons. CNP
(1), Tetherin (2, 3), and GBP5 (4), proteins of the IFITM family (5, 6), and SERINC5 (7, 8)
block particle assembly, block particle release, or reduce HIV-1 particle infectivity,
demonstrating that late steps of the lentiviral replication cycle can be targeted by host
cell defenses. The cellular glycoprotein LGALS3BP (galectin 3 binding protein, also
known as 90K) is a secreted antiviral protein that has been identiﬁed by us (9) and
others (10) to interfere with late steps of human immunodeﬁciency virus type 1 (HIV-1)
biogenesis, resulting in poor infectivity of released virions. 90K was originally identiﬁed
as a tumor antigen, and its expression is also upregulated in the context of HIV-1 and
hepatitis C virus (HCV) infections, reaching secreted protein levels in the microgram-
per-milliliter range in body ﬂuids (11–13). 90K is composed of a scavenger receptor
cysteine rich-like domain of known structure (14), a BTB (broad-complex, tramtrack, and
bric-à-brac)/POZ (poxvirus and zinc ﬁnger) domain, an IVR (intervening region) domain,
and a C-terminal part without substantial homology to known protein domains (15).
Upon completion of posttranslational modiﬁcations, the highly glycosylated 90K is
secreted in an ERGIC-53-regulated manner (16) and associates with the extracellular
matrices of various tissues, where it oligomerizes to ring-like and linear structures (15,
17, 18). Physiological functions of the extracellular protein may comprise immuno-
modulation and modulation of proliferation, motility, migration, and adhesion of cells
via interaction with cell surface receptors (19). Speciﬁcally, 90K-mediated induction of
cell signaling involves upregulation of cytokine production, including interleukin 2
(IL-2), IL-6, granulocyte-macrophage colony-stimulating factor (GM-CSF), and tumor
necrosis factor alpha (TNF-) (19–21), which may contribute to an antiviral state. We
have shown previously that 90K expressed within HIV-1-producing cells mediates the
antiviral activity against HIV-1, but not exogenously added secreted protein, suggesting
an intracellular mode of antiviral action (9). Inhibition correlated with reduced viral
incorporation of mature HIV-1 gp120 and gp41 glycoproteins and was accompanied by
reduced HIV-1 gp160 Env precursor processing. Importantly, small interfering RNA
(siRNA)-mediated reduction of 90K protein expression increased particle infectivity of
released virions in TZM-bl cell lines by 10-fold and enhanced the spread of HIV-1 Ba-L
in primary macrophages up to 5-fold, indicating that physiological levels of 90K
expression contribute to HIV-1 restriction (9).
Investigating the ability of closely related orthologs of restriction factors to inhibit viral
infections is a valuable approach to identifying domains that determine antiviral activity
and to shedding light on the mode of antiviral action. Here, we address the species
speciﬁcity of 90K orthologs to restrict lentiviruses, and we identify functional and structural
determinants of the antiviral activity of 90K.
RESULTS
Species-speciﬁc antiviral activity of 90K proteins. The coding sequence of 90K is
highly conserved within primates, with amino acid homologies ranging from 90 to 98%
between individual nonhuman primate 90K proteins and human 90K (Fig. 1A). To
explore the species speciﬁcity of 90K’s antiviral activity, we analyzed the infectivity of
HIV-1 particles generated in producer HEK293T cells expressing heterologous, C-terminally
myc-tagged 90K proteins. Importantly, HEK293T cells lack detectable expression of endog-
enous 90K protein (9) and therefore represent a suitable system for heterologous
expression studies. The infectivity of released particles, deﬁned as infectivity per
nanogram of HIV-1 p24 capsid in the culture supernatant, was diminished by 70% by
human 90K-myc (Fig. 1B), conﬁrming our previous data (9). All seven tested nonhuman
90K proteins, with the surprising exception of 90K from rhesus macaques, reduced
particle infectivity to similar extents. Anti-myc immunoblotting conﬁrmed that all
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proteins were expressed (Fig. 1B). These results point toward an evolutionarily con-
served, but not universal, antiviral activity of 90K proteins among primate species that
manifests itself as a decreased infectivity of secreted HIV-1 particles.
90K inhibits HIV-1 by impairing Env incorporation into particles. Human 90K-
mediated reduction of particle infectivity correlates with decreased levels of incorpo-
rated gp120 glycoproteins and is accompanied by lowered Env cell surface expression
and reduced cleavage efﬁciency of the glycoprotein precursor (9). Here, we investigated
the protein composition of virus particles produced in the presence of primate 90K
proteins and determined the cleavage efﬁciency of the Env polyprotein precursor
within the respective HIV-1 producer cells by quantitative immunoblotting. Levels of
virus-associated mature gp120 were reduced 54 to 66% by human 90K and the six
active nonhuman primate variants but were not statistically signiﬁcantly altered in the
presence of rhesus macaque-derived 90K-myc (Fig. 2A). Proteolytic cleavage of the
glycoprotein precursor, however, was impaired by 90K proteins of all the nonhuman
primate species, including the inactive rhesus macaque protein, by 25 to 39%, while
Gag processing remained intact (Fig. 2B). Of note, levels of viral gp120 incorporation
and of mature gp120 expression both correlated positively with the relative particle
infectivity (Fig. 2C and D), and viral gp120 incorporation and gp160 processing corre-
lated positively with each other (Fig. 2E). Similarly to gp160 processing, cell surface
levels of HIV-1 gp120 were reduced by all 90K orthologs by 29 to 47% (Fig. 2F and G).
Importantly, neither expression of human 90K nor expression of rhesus macaque 90K
altered overall protein trafﬁcking and secretion, as evidenced by the fact that extra-
cellular concentrations of migration inhibition factor (MIF), macrophage colony-
stimulating factor (M-CSF), and monocyte chemoattractant protein 1 (MCP-1) remained
stable in the context of 90K expression (Fig. 2H), whereas they were effectively
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decreased by brefeldin A treatment, as assessed by Luminex-based multiplex assays
(Fig. 2I). Taking these ﬁndings together, 90K’s ability to interfere with glycoprotein
precursor cleavage and to lower the pool of HIV-1 Env at the plasma membrane may
be required, but not sufﬁcient, for reduction of HIV-1 particle infectivity. Rather, speciﬁc
impairment of incorporation of mature gp120 into nascent virions appears to be the
primary mode of action of 90K.
Speciﬁcity of anti-lentiviral activity of 90K. We next tested the ability of 90K-myc
proteins to inhibit lentiviruses other than HIV-1. The particle infectivity of HIV-2 was
reduced by all tested primate orthologs, including the rhesus macaque ortholog, albeit
to milder extents than that of HIV-1 (Fig. 3A and B). Simian immunodeﬁciency virus
from macaques (SIVmac) and SIV from sooty mangabey monkeys (SIVsmm) were inhib-
ited by all tested primate 90K proteins, with the exception of rhesus macaque-derived
90K, which only mildly reduced the infectivity of these SIVs to a level comparable to
that for HIV-2, without, however, reaching statistical signiﬁcance (Fig. 3C and D). SIV
from African green monkeys (SIVagm) and SIV from chimpanzees (SIVcpz) were suscep-
tible to inhibition by all tested 90K proteins, including the rhesus macaque-derived
factor (Fig. 3E and F). However, due to the lack of availability of antibodies recognizing
SIVsmm, SIVagm, and SIVcpz capsids, we cannot rule out an inhibitory effect of 90K on the
release of these viruses, which potentially contributes to the small amount of infectivity
released into the supernatant. These data indicate that inhibition by human and most
nonhuman primate 90K proteins is not HIV-1 speciﬁc but is also directed against other
lentiviruses. Among primate 90K proteins, rhesus macaque 90K is unique in its inability
to diminish the particle infectivity of the tested HIV-1 strain and in its low potency
against SIVmac and SIVsmm strains, despite 89-to-97% amino acid identity with active
primate 90K proteins.
Toward a minimal antiviral 90K variant. We have shown previously that a
shortened version of human 90K-myc, comprising solely domains 2 and 3 [hu 90K(127–
408)], is at least as active as wild-type 90K-myc (9). Starting from this observation, we
aimed at further narrowing down the minimal region required for antiviral activity. For
this purpose, we generated a set of shortened variants of 90K-myc (Fig. 4A). Conﬁrming
our previous results (9), particle infectivity was slightly more efﬁciently reduced by
90K(127–408) than by wild-type 90K (Fig. 4B). Further C-terminal truncation [90K(127–
358) and 90K(127–308)] did not curtail the antiviral activity. On the other hand, further
stepwise truncation of the N terminus slightly decreased [90K(157–408)] or abrogated
[90K(207–408)] antiviral activity and reversed the gain of antiviral activity introduced by
C-terminal truncation [90K(157–358) and 90K(207–308)]. Finally, domains 2 and 3
expressed individually did not exhibit any antiviral activity (Fig. 4B), suggesting that a
structural entity consisting of both domains is essential for full antiviral potential.
FIG 2 Legend (Continued)
indicate statistical signiﬁcance (P  0.05); n.s., not signiﬁcant. (B) Producer cell lysates were analyzed by immunoblotting for gp160 processing
using anti-gp120 and for Gag expression using anti-p24. Relative gp160 processing was determined by expressing the level of mature gp120
as a percentage of the whole-Env (gp120  gp160) signal. Band intensities were quantiﬁed by infrared-based imaging. The bar diagrams show
mean values from 3 to 7 independent experiments  SEM. (C) Correlative analysis of gp120 Env content per p24 CA and HIV-1 particle
infectivity (infectivity per nanograms of p24) in the supernatants of cells expressing the indicated 90K-myc protein or the vector. (D) Correlative
analysis of HIV-1 particle infectivity and levels of mature gp120 per whole-Env expression in producer cell lysates expressing the indicated
90K-myc protein or the vector. (E) Correlative analysis of levels of gp120 viral incorporation and levels of mature gp120 per whole-Env
expression in producer cell lysates. In panels C to E, symbols represent the values for individual transfections. The Pearson correlation coefﬁcient
r and the corresponding P value were calculated using GraphPad Prism software. (F) HEK293T cells were mock transfected or cotransfected with
the indicated HIV-1 proviral DNAs and constructs. At 48 h posttransfection, intact cells were immunostained for HIV-1 Env surface expression
and analyzed by ﬂow cytometry. In the dot plots, the HIV-1 Env levels are plotted against GFP. Numbers inside the boxes indicate the mean
ﬂuorescence intensity (MFI) of the HIV-1 Env signal in the respective gates. (G) The levels of cell-surface-exposed HIV-1 Env in each sample were
quantiﬁed on GFP-positive cells in the R3 gate relative to the MFI of GFP-negative cells in the R2 gate, which serve as an internal reference.
The relative cell surface expression levels of HIV-1 Env are depicted, with values for HIV-1 Env expression in vector-transfected cells set to 100%.
Shown are mean values from six independent experiments  SEM. (H) HEK293T cells were either mock treated or transfected with an empty
vector or 90K-encoding plasmids. Supernatants were harvested at days 1 and 2 posttransfection and were subjected to Luminex-based
multiplex assays according to the manufacturer’s instructions. Secretion into supernatants was analyzed for MIF, M-CSF, and MCP-1 (CCL2); all
concentrations are given in picograms per milliliter. (I) HEK 293T cells were either mock treated or brefeldin A treated for 6 h. Supernatants
were then subjected to Luminex-based multiplex assays as outlined for panel H.
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Expression of authentic 90K and the three highly active 90K versions [90K(127–408),
90K(127–358), and 90K(127–308)] resulted in secretion of virus particles displaying
80% reduced amounts of mature incorporated gp120. In contrast, expression of
mildly active [90K(157–408), 90K(157–358)] and inactive [90K(207–408), 90K(207–308),
90K(127–250), and 90K(251–408)] 90K versions resulted in particles with normal gp120
Env (Fig. 4C). Proteolytic processing of the gp160 precursor was diminished by most
shortened 90K versions, including some displaying mild or even absent antiviral activity
(Fig. 4D). Finally, levels of incorporated gp120 and of mature gp120 expression both
correlated positively with the relative particle infectivity (Fig. 4E and F), and levels of
incorporated gp120 and of mature gp120 expression correlated positively with each
other (Fig. 4G). These results reinforce the notions that the antiviral effect of 90K is
mediated primarily via reduction of HIV-1 Env incorporation and that the observed
interference with HIV-1 Env gp160 precursor processing may be required but is not
sufﬁcient.
Genetic humanization renders a minimal version of rhesus macaque 90K
antiviral. Based on interspecies comparison (Fig. 1) and analysis of minimal human 90K
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variants (Fig. 4), we embarked on a ﬁne-mapping study with the goal of deﬁning single
amino acids that are crucial for 90K’s antiviral activity. A minimal version of 90K from
rhesus macaques, expressing solely domains 2 and 3 [rhe 90K(127–408)] was inactive,
whereas its human counterpart showed strong antiviral activity (Fig. 5A). The two
orthologs differ by 18 amino acids (aa) dispersed on both domains in this region (Fig.
5B). Chimeric constructs consisting of human domain 2 and rhesus macaque domain 3
or vice versa displayed no antiviral activity (Fig. 5C, blue bars). We then introduced
individual, “humanizing” point mutations into the rhesus macaque portions of these
chimeric constructs. Indeed, selected individual mutations in either rhesus macaque
domain resulted in a gain of antiviral activity, with V142A and F208L in rhesus macaque
domain 2 and L268V in rhesus macaque domain 3 representing the most inﬂuential
exchanges in each construct, respectively (Fig. 5C). In order to probe whether selected
amino acid exchanges are sufﬁcient for rescuing the antiviral activity in the context of
the authentic rhesus macaque protein, we transferred them individually into the
full-length protein and into the short version of rhesus macaque 90K-myc [rhe 90K(127–
408)] (Fig. 5D). Interestingly, introduction of V142A, but not L268V, into the short version
of rhesus macaque 90K-myc resulted in a gain of antiviral activity that was in the same
range as the short human version, and coincided with reduced gp120 incorporation
(Fig. 5D). Although V142A introduction into the full-length rhesus macaque protein
decreased the infectivity of virus particles 2-fold, these values did not reach statistical
signiﬁcance, pointing toward additional determinants in the scavenger receptor
cysteine-rich (SRCR)-like domain and the C-terminal domain of the rhesus macaque
factor that may negatively regulate antiviral activity. In addition, no loss of antiviral
activity in either the full-length or the short version of human 90K was observed after
the introduction of the reciprocal, “simianizing” A142V change (Fig. 5D), suggesting that
other residues in the human context can compensate for V142. Titration of active and
inactive rhesus macaque 90K constructs indicated that active variants can be outbal-
anced by inactive constructs (Fig. 5E).
Crystal structure of the BTB/POZ domain of human and rhesus macaque 90K.
Given that a single amino acid exchange in the BTB/POZ domain of the short version
of rhesus macaque 90K was sufﬁcient to restore antiviral activity, we next set out to
structurally characterize the environment of this residue within the short versions of the
rhesus macaque and human 90K proteins. However, 90K has a tendency to oligomerize
beyond homodimerization by forming ring-like structures of variable size (15), and this
tendency was also observed for a 90K construct encompassing domains 2 and 3 (data
not shown), rendering the structure analysis complicated. Since the individual BTB/POZ
domains of both the human and rhesus macaque 90K proteins do not feature a similar
oligomerization tendency, and given that a single amino acid exchange in the BTB/POZ
domain of the short version of rhesus macaque 90K was sufﬁcient to restore antiviral
activity, we determined the structures of the individual BTB/POZ domains from the
human and rhesus macaque 90K proteins. We expressed modiﬁed 90K BTB/POZ
domains that contained three additional residues at the N terminus (aa 124 to 250;
based on secondary structure predictions and comparisons with available structures of
other BTB/POZ domains) in Drosophila melanogaster S2 cells and puriﬁed both proteins,
which behaved as a single oligomeric species in solution, to homogeneity. We obtained
FIG 4 Legend (Continued)
statistical signiﬁcance (P  0.05); n.s., not signiﬁcant. Lysates of the producer cells were immunoblotted with anti-myc and anti-MAPK antibodies.
(C) Sucrose cushion-puriﬁed progeny virions were analyzed by immunoblotting, and band intensities were quantiﬁed by infrared-based imaging.
gp120 incorporation, deﬁned as the ratio of gp120 signal intensity to p24 signal intensity, was calculated from 3 to 6 independent experiments.
Values obtained in the absence of 90K were set to 100%. (D) gp160 processing in cell lysates was determined by immunoblotting using the
indicated antibodies. Band intensities were quantiﬁed by infrared-based imaging, and the percentage of mature gp120 from total Env protein
is depicted. The bar diagrams show the arithmetic means  SEM from 3 to 5 independent experiments. (E) Relative levels of gp120 viral
incorporation and particle infectivity, obtained in the presence of the human 90K variants used, are plotted against each other. (F) Levels of
mature gp120 per whole-Env expression in producer cell lysates and relative levels of particle infectivity are plotted against each other. (G)
Relative levels of gp120 viral incorporation and levels of mature gp120 per whole-Env expression in producer cell lysates are plotted against each
other. For these values, the Pearson correlation coefﬁcient r and the corresponding P value are indicated. The open circles depict the values
obtained in the absence of 90K expression.
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FIG 5 Genetic humanization renders a minimal version of rhesus macaque 90K antiviral. (A) HEK293T cells were cotransfected with HIV-1 proviral
DNA and the indicated 90K constructs. At 48 h posttransfection, the infectivity of cell-free particles was measured as infectivity per nanogram
of p24 capsid antigen in the supernatant. Values obtained in the absence of 90K were set to 100%. Shown are arithmetic means  SEM from
3 to 8 independent experiments. Asterisks indicate statistical signiﬁcance (P  0.05); n.s., not signiﬁcant. (B) The human and rhesus macaque
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crystals of the human protein that diffracted to 2.1 Å (crystallographic statistics are
listed in Table 1) and crystals of the rhesus macaque protein diffracting to 3.3 Å. The
structure of the human ortholog was determined by the multiwavelength anomalous
dispersion (MAD) method as described in Materials and Methods. The human 90K
BTB/POZ domain structure was subsequently used as a search model to determine the
structure of the rhesus macaque ortholog by the molecular replacement method. The
human and rhesus macaque structures contained 1 and 3 homodimers per asymmetric
unit, respectively. For further analysis, the rhesus homodimer comprising all residues
with the lowest mean B value after crystallographic reﬁnement, indicating the highest
degree of order in this part of the structure, was selected.
The experimental electron density maps of both BTB/POZ domains allowed us to
trace the entire molecule comprising residues 129 to 250. The resulting atomic models
revealed tightly intertwined homodimers with the canonical BTB/POZ homodimer fold,
consisting of both -helices and -sheets (Fig. 6A and C). As expected from the
sequence alignment, the two BTB/POZ domains are structurally conserved, with a DALI
score of 22.6 and root mean square deviations (RMSD) of 0.6 Å for pairwise compar-
FIG 5 Legend (Continued)
BTB/POZ and IVR domains were aligned using Clustal Omega (41) and ESPript (42). Conserved secondary-structure elements, including -helices,
310-helices, -strands, and -turns taken from the human BTB domain structure, are shown above the alignment (, , , and TT, respectively).
Nonconserved residues are highlighted by a red background; a green background indicates conserved cysteines, and their disulﬁde connectivity
is drawn in green below the alignment. (C) HEK293T cells were ﬁrst cotransfected with HIV-1 proviral DNA and constructs encoding the indicated
interspecies chimeras and then processed as for panel A. Shown are arithmetic means SEM from 3 independent experiments. (D) HEK293T cells
were cotransfected with HIV-1 proviral DNA and the indicated constructs and were processed as for panel A. Shown are arithmetic means  SEM
from 3 independent experiments. (E) HEK293T cells were cotransfected with HIV-1 proviral DNA and combinations of plasmids encoding for short
versions of wild-type rhesus macaque 90K-myc [127-408 (wt)] and of rhesus macaque 127-408 (V142A). Both 90K variants were titrated in the
opposite direction, covering plasmid ratios of 04, 13, 1.52.5, 22, 2.51.5, 31, and 40. Transfected cells were processed as for panel A.
TABLE 1 Data collection, phasing, and reﬁnement statistics
Parametera
Value(s) for 90K-BTBb
Human Rhesus macaque
Data collection statistics
Space group P 31 21 I 41 22
Cell dimensions
a, b, c (Å) 70.34, 70.34, 105.51 181.76, 181.76, 173.52
 ,  (°) 90.0, 90.0, 120.0 90.0, 90.0, 90.0
No. of molecules/AU 2 6
Resolution (Å) 50–2.08 (2.21–2.08) 50–3.3 (3.39–3.3)
Rmeas 0.12 (1.591) 0.141 (8.242)
I/ (I) 14.46 (1.42) 21.70 (1.05)
CC1/2 0.99 (0.79) 1.00 (0.39)
Completeness (%) 99.2 (94.9) 100.0 (99.9)
Redundancy 18.6 (17.2) 56.9 (58.7)
Reﬁnement statistics
Resolution (Å) 20.77–2.08 (2.21–2.08) 49.17–3.3 (3.46–3.3)
No. of reﬂections 18,506 22,100
Rwork/Rfree 0.208/0.243 0.301/0.287
No. of atoms
Protein 1,861 5,546
Solvent 41 0
B factors (Å2), protein 50.62 195.59
RMS deviations
Bond length (Å) 0.010 0.007
Bond angle (°) 1.03 0.93
Ramachandran plotc (%)
Favored 99.2 96.1
Allowed 0.8 3.6
Outliers 0 0.3
aOne crystal was used to collect each of the diffraction data sets used to determine the crystal structures.
AU, asymmetric unit; CC1/2, Pearson correlation coefﬁcient between two random half data sets.
bValues in parentheses are those for the highest-resolution shell.
cRamachandran statistics were calculated with MolProbity.
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isons of 119 structurally equivalent C atoms. The seven residues that are divergent
between the domains of the two species are distributed over the entire molecule (Fig.
5B and 6B).
Residue 142 (alanine in human 90K, valine in rhesus 90K), the mutation of which
resulted in a gain of antiviral activity in the context of the short variant of rhesus macaque
FIG 6 Crystal structure of human and rhesus macaque BTB. (A and C) Ribbon diagrams of the human BTB homodimer, with one subunit shown in gray and
the other colored in gradations from the N to the C terminus (blue to red) according to the color scales in the bars underneath. Disulﬁde bonds are shown
as green sticks. (B) Superposition of human BTB and rhesus macaque BTB, with the two subunits displayed in gray (human BTB) and green (rhesus macaque
BTB). Side chains of residues that are divergent between the human and rhesus macaque 90K proteins are shown as sticks and are colored according to atom
type (gray and green for carbon of human BTB and rhesus macaque BTB, respectively; red and blue for oxygen and nitrogen, respectively). (D) Closeup view
of the homodimerization interface of superposed human BTB and rhesus macaque BTB. Side chains of residue 142, which provides a gain of antiviral activity
in the context of the short version of rhesus macaque 90K-myc, and the conserved residue A178, which makes an additional hydrophobic contact with V142
(dashed line), are shown as sticks. (E and F) The molecular surfaces of the human (E) and rhesus macaque (F) 90K BTB domain are displayed in gray and green,
respectively, as in panel B. The surface area corresponding to A142 (human BTB) or V142 (rhesus macaque BTB) is shown in red.
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90K, is located on helix 1 and participates in the homodimer interface. The buried
interface areas of the hydrophobic V142 (rhesus) and A142 (human) residues in the respec-
tive BTB domain homodimer interfaces amount to 40.90 and 34.58 Å2 for the rhesus and
human BTB domains, respectively, suggesting that a V142A mutation does not signiﬁcantly
modulate homodimer stability. In line with this observation, the calculated binding ener-
gies contributed by these two residues to homodimer formation (0.64 and 0.5 kcal/mol for
V142 and A142, respectively) do not differ signiﬁcantly, supporting the hypothesis that the
differential antiviral activity of human and rhesus 90K proteins is not related to differential
stability of the homodimer. In contrast, the accessible surface area of residue 142 within the
homodimer (i.e., the area that is accessible at the surface of a dimerized BTB domain) differs
by 15 Å2 (47.66 Å2 and 64.08 Å2 for the human and rhesus BTB domains, respectively),
suggesting that the introduction of valine at this position results in a larger hydrophobic
patch at the surface of the rhesus BTB domain that potentially stabilizes a direct interaction
with either a different protein or another domain of 90K, thereby interfering with antiviral
activity.
DISCUSSION
Given the high degree of sequence conservation between 90K proteins from
primate species, the overall preservation of the antiviral activity of 90K against lentivi-
ruses was expected. However, as a notable exception, 90K protein from rhesus ma-
caques failed to reduce HIV-1, SIVmac, or SIVsmm infectivity, despite sharing 89-to-97%
amino acid identity with its primate counterparts. Interestingly, HIV-2, SIVagm, and
SIVcpz were sensitive to all primate 90K proteins, including the rhesus macaque-derived
protein, arguing against a general misfolding or nonfunctionality of the latter. Although
human 90K is antiviral against all R5 and X4 HIV-1 strains tested, reaching infectivity
reduction ranges between 65 and 96% by heterologously expressed 90K and up to 91%
by endogenous 90K (9), it will be interesting to analyze, in the future, whether different
HIV-1 strains display different species speciﬁcity with regard to 90K-mediated inhibition,
and whether this can be modulated by heterologous exchange of Env. Along this line,
analysis of HIV-1–HIV-2 chimeric viruses may help to explain the overall inferior
susceptibility of HIV-2 to 90K-mediated restriction, compared to HIV-1.
Analysis of active and inactive 90K proteins, either derived from different primate
species or engineered by mutation, revealed that modest impairment of HIV-1 gp160
processing and reduction of cell surface pools of HIV-1 Env are conserved between all
tested primate 90K proteins, including the inactive rhesus macaque protein. Further-
more, these features are preserved in most shortened versions of human 90K. We thus
conclude that mere inhibition of gp160 processing and lowering of cell surface HIV-1
Env expression at observed efﬁciencies do not directly imply reduced infectivity of
virions. In contrast, 90K-mediated reduction of the abundance of mature HIV-1 Env
glycoproteins seems to be the essential parameter directly linked to antiviral activity.
Importantly, protein trafﬁcking and secretion remained intact in cells expressing human
or rhesus 90K, excluding the possibility of a general inﬂuence of 90K proteins on the
efﬁciency of these cellular processes. These data are in line with our earlier notion of
unaltered surface CD4 protein expression (9) and fully maintained metabolic activity (9),
as well as with the lack of modulation of HIV-1 p24 capsid secretion in HIV-1-producing,
90K-expressing cells. Although we favor the idea of a role of 90K in inhibiting gp120
incorporation, we cannot formally exclude the possibility that 90K induces, at least
partially, instability and/or shedding of virus-associated Env.
As one possible conclusion, impairment of gp160 processing and reduction of cell
surface HIV-1 Env amounts may be required, but not sufﬁcient, for mediating the defect
in gp120 incorporation and for exerting antiviral activity. Alternatively, the former
features may represent a “bystander” effect of 90K that is uncoupled from their ability
to impede viral incorporation of mature glycoproteins. From a broader perspective,
these ﬁndings suggest that incorporation of HIV-1 glycoproteins may be efﬁcient even
under conditions in which only low numbers of mature Env glycoproteins are being
synthesized. In contrast, reduction of viral incorporation of mature Env glycoproteins to
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levels below the reported amounts of 7 to 14 trimers of HIV-1MN Env per virion (22, 23)
appears to represent a vulnerable point of lentiviral replication and might represent a
target for antiviral drug development in the future.
Interspecies comparison, paired with the analysis of minimal versions of 90K, led to
the ﬁnding that “humanization” of the BTB/POZ domain at position 142 in the context
of a minimal version of rhesus macaque 90K, consisting solely of domains 2 and 3 of the
authentic factor [rhe 90K(127–408)], was sufﬁcient to restore antiviral activity. While we
identiﬁed, in total, three amino acid exchanges in the BTB/POZ domain that conferred
antiviral activity on the previously inactive rhesus macaque-human chimera, V142A
represented the most potent exchange. Although this is a conservative amino acid
exchange, documented examples of V-to-A polymorphisms illustrate profound biolog-
ical relevance. These include the V226A exchange in the Chikungunya virus (CHIKV) E1
protein, conferring the ability of the virus to expand its vector usage (24); the acqui-
sition of resistance by HIV-1 Gag to antiviral compounds through an A-to-V change in
the CA/SP1 cleavage site of Gag (25); and the abolishment of signaling by the
ATP-binding cassette transporter A1 through the introduction of A937V (26). The
structures of both BTB/POZ domains showed that residue 142 is located at the edge of
the homodimer interface, but the larger hydrophobic valine side chain results in a
larger hydrophobic patch at the surface of the homodimer. The gain of function
induced by V142A in rhe 90K(127–408) could originate either from a direct effect of the
mutation (e.g., a direct interaction) or from an indirect effect (e.g., modiﬁcation of the
90K oligomeric nature affecting protein-protein interactions). It remains elusive
whether the observed effect is due to interaction with a protein partner or with a
different 90K domain. Although previous attempts failed to demonstrate an interaction
of HIV-1 Env and human 90K in coimmunoprecipitation experiments (9), we cannot rule
out the possibility of a weak or transient interaction between Env and 90K, which may
contribute to, or even be crucial for, 90K’s antiviral activity. In the future, it will be
necessary to identify potential species-speciﬁc cellular or viral factors which may
interact with 90K in a manner that modulates antiviral activity. A translational perspec-
tive may consist of reinforcing 90K’s antiviral potential in order to render it more
effective, e.g., by speciﬁcally increasing its expression levels or by designing cell-
permeant small molecules that stabilize a cellular interaction that is essential for the
antiviral mode of action. Future studies should also elucidate whether HIV-1 can evolve
to full 90K resistance after long-term passage in 90K-expressing cells and should
determine the genomic location of the viral escape mutations, allowing the design of
speciﬁc antiviral strategies.
V142A was not sufﬁcient to entirely restore antiviral activity to the full 90K protein
from rhesus macaques, suggesting that yet-to-be-identiﬁed determinants within the
N-terminal SRCR domain and the poorly characterized C-terminal domain negatively
regulate the antiviral capacity of rhesus macaque 90K. Adding another layer of com-
plexity, the antiviral 90K proteins from African green monkeys and baboons share V142
with the inactive 90K protein from rhesus macaques (data not shown). In addition, no
loss of antiviral activity was observed for either full-length human 90K or hu 90K(127–
408) after introduction of the reciprocal, “simianizing” A142V exchange, suggesting that
other residues in the human protein context can compensate for V142. Taken together,
our results suggest that a particular quaternary arrangement of 90K domains 2 and 3
is required for antiviral activity. The interface stabilizing this arrangement likely involves
residue 142 within the BTB/POZ domain, and in the rhesus context, a valine at this
position interferes with this functional quaternary arrangement. Of note, the antiviral
activities of 90K proteins from African green monkeys and baboons, as well as that of
“simianized” A142V human 90K, indicate that this interference can be overcome in the
context of other 90K orthologs, likely due to other residues involved in the quaternary
interface. Future studies to elucidate the molecular mechanism of species-speciﬁc
antiviral activity should therefore aim for a structural characterization of full-length 90K,
or at least a 90K construct encompassing domains 2 and 3 at atomic resolution.
However, 90K has the tendency to oligomerize beyond homodimerization by forming
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ring-like structures of variable size (15), rendering structure analysis complicated. This
tendency has also been observed for a 90K construct encompassing domains 2 and 3
(data not shown).
Finally, while our study speciﬁcally investigated the species speciﬁcity of 90K
regarding the direct interference with HIV-1 particle infectivity, further work is required
to identify or exclude potential species-speciﬁc differences regarding interferon (IFN)-
mediated regulation of 90K expression and abilities to induce antiviral and inﬂamma-
tory cytokines.
In conclusion, we established the species speciﬁcity of the antiviral protein 90K, and
species-speciﬁc comparison enabled us to obtain important insight into its antiviral
mechanism. Further studies are required in order to characterize 90K’s detailed mode
of action and to elucidate potential evasion strategies that may emerge in virus strains
that are forced to propagate in 90K-expressing cells.
MATERIALS AND METHODS
Cells. HEK293T cells (obtained from the American Type Culture Collection [ATCC]) and TZM-bl cells
(obtained from the NIH AIDS Reagent Program) were cultured as recommended. HEK293T cells were
transfected by calcium phosphate DNA precipitation (Clontech) or with polyethylenimine (PEI) (Polyplus,
Illkirch, France) as a transfection reagent. Brefeldin A was purchased from BioLegend and was used at a
ﬁnal concentration of 5 g/ml.
Plasmids. pcDNA6 and pcDNA6.90K-myc plasmids were kindly provided by Ji Hee Lee, South Korea
(27). cDNAs encoding 90K-myc orthologs (cpz, chimpanzee [Pan troglodytes]; ora, orangutan [Pongo
pygmaeus]; agm, African green monkey [Cercopithecus aethiops tantalus]; rhe, rhesus macaque [Macaca
mulatta]; owl, owl monkey [Aotus trivirgatus]; gib, gibbon, [Hylobates lar]; bab, baboon [Papio hama-
dryas]) were ampliﬁed by PCR and cloned into the pcDNA6/myc-His vector backbone using BamHI/XbaI
sites. The shortened variants of 90K-myc all contained the authentic signal peptide and were generated
by insertion into the pcDNA6/myc-His backbone using BamHI and XbaI or HindIII and XbaI. Chimeras
were generated by splicing by overhang extension PCR (SOE-PCR) and were inserted in the pcDNA6/
myc-His backbone using BamHI/XbaI sites. For SOE-PCR, ﬁrst, domains of each species were ampliﬁed
using primers with overlaps for the proximate domains of the various species, respectively. In a following
PCR, products with overlaps were ampliﬁed to one chimeric product. Single point mutations were
introduced by site-directed mutagenesis (Stratagene). The proviral HIV-1NL4.3 DNA was obtained from
Oliver Keppler. The expression plasmid for proviral HIV-27312A was provided by Beatrice Hahn.
Lentiviral particle infectivity assay. The infectivity of lentiviral particles was assessed by applying a
standardized TZM-bl-based ﬁreﬂy luciferase assay or beta-galactosidase assay. Readouts were obtained
luminometrically (RLU, relative light units). For the calculation of HIV-1 and HIV-2 particle infectivity, lumino-
metric counts were divided by the content of p24, which was quantiﬁed by an anti-HIV-1 p24 enzyme-linked
immunosorbent assay (ELISA). For the calculation of SIVmac particle infectivity, luminometric counts were
divided by the content of p27, which was quantiﬁed by anti-SIVmac p27 ELISA. Luminometric activity was
analyzed with a Centro LB 960 Microplate luminometer and Ascent 2.0 software.
Anti-p24 and anti-p27 antigen ELISA. For quantiﬁcation of HIV-1 p24 capsid antigen in the culture
supernatant, a homemade sandwich ELISA was used (28). A commercial ELISA (ABL, Inc.) was used for
detection of SIVmac239 p27 capsid antigen.
Antibodies. The following antibodies/antisera were used for immunoblotting: mouse anti-myc
(provided by Jens von Einem), goat anti-myc (Novus Biologicals), rabbit anti-mitogen-activated protein
kinase (anti-MAPK) (Santa Cruz), mouse anti-HIV-1 p24 (Exbio), and rabbit anti-HIV-1 gp120 (provided by
Valerie Bosch). For HIV-1 Env staining on nonpermeabilized cells, experiments were performed with
anti-gp120 antibody 2G12 or 10-1074 (obtained from the NIH AIDS Reagent Program).
Immunoblotting. Cells were lysed with M-PER Mammalian protein extraction reagent (Pierce), and
virions were prepared from supernatants by ultracentrifugation through a 20% (wt/vol) sucrose cushion.
Proteins were run on a 12.5% or 7.5% SDS-PAGE gel and were transferred to nitrocellulose membranes.
Blocked membranes were incubated with primary antibodies. Secondary antibodies conjugated to Alexa
Fluor 680/800 ﬂuorescent dyes were used for detection by the Odyssey Infrared Imaging System (Li-Cor
Biosciences) with quantiﬁcation by Odyssey software.
HIV-1 Env surface staining. Upon transient cotransfection with proviral plasmids encoding green
ﬂuorescent protein (GFP) and 90K-myc-encoding constructs, HEK293T cells were harvested after 48 h.
Cells were stained with the primary anti-gp120 antibody (2G12) followed by secondary staining with the
Alexa Fluor 647-conjugated goat anti-human IgG (Invitrogen) (9, 29). After the surface HIV-1 Env staining,
cells were ﬁxed with paraformaldehyde (PFA) and analyzed for surface HIV-1 Env levels. Due to the
disproportional expression of Env inside the cell (high) as opposed to on the cell surface (low) in
provirally transfected HEK293T cells (4, 9), we restricted the analysis to gate R3, which contains cells
driving sufﬁciently high viral gene expression to yield detectable cell surface Env, and normalized these
signals to the respective R2 gate. Flow cytometry analysis was performed using FACSCalibur with BD
CellQuest Pro 4.0.2 software (BD Pharmingen) and FlowJo V10 software (FlowJo).
Expression and puriﬁcation of the 90K BTB domains. The cDNA corresponding to the BTB
domains of human and rhesus macaque 90K proteins, comprising residues 124 to 250, was cloned into
a modiﬁed Drosophila S2 expression vector described previously, and transfection was performed as
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reported earlier (30). For large-scale production, cells were induced with 4 mM CdCl2 at a density of
approximately 7  106 cells/ml for 6 days and were pelleted, and the soluble ectodomain was puriﬁed
by afﬁnity chromatography from the supernatant using a StrepTactin XT Superﬂow column followed by
size exclusion chromatography (SEC) using a Superdex 200 column in 10 mM Tris (pH 8.0), 100 mM NaCl.
For crystallization purposes, the afﬁnity tag was removed by enterokinase digestion (EKMax; Invitrogen,
San Diego, CA, USA) according to the manufacturer’s instructions, followed by removal of uncleaved
protein using Strep-Tactin afﬁnity chromatography and SEC. In addition, human BTB was enzymatically
deglycosylated using endoglycosidase D (New England Biolabs, Frankfurt, Germany) according to the
manufacturer’s instructions, followed by removal of the glycosidase and the cleaved sugar chains by SEC.
Pure protein was concentrated to approximately 6 mg/ml.
Crystallization and structure determination. Crystals of BTB were grown at 293K using the
hanging-drop vapor diffusion method in drops containing 1 l puriﬁed protein (6 mg/ml in 10 mM Tris
[pH 8.0], 100 mM NaCl) mixed with 1 l reservoir solution containing 29% polyethylene glycol 4000 (PEG
4000), 0.2 M MgCl2, 0.1 M Tris (pH 8.5), and 10% sucrose (for rhesus macaque BTB) or 9% PEG 8000, 0.2
M zinc acetate, and 0.1 M imidazole (pH 6.8) (for human BTB). Diffraction quality rod-like crystals
appeared after 4 to 5 days and were ﬂash-frozen either in mother liquor (for rhesus macaque BTB) or in
mother liquor containing 25% ethylene glycol (for human BTB). Data collection was carried out at PETRA
III (DESY; P14) and the Synchrotron Soleil (Proxima2). Data were processed, scaled, and reduced with XDS
(31), Pointless (32), and programs from the CCP4 suite (33). A multiwavelength anomalous dispersion
(MAD) data set was collected from two independent volumes of a single human BTB crystal around the
K-edge of zinc, and the structure was determined using the Phenix AutoSol Wizard (34). The structure of
rhesus macaque BTB was determined by the molecular replacement method using Phaser (35) with the
human BTB structure as the search model. Model building was performed using Coot (36), and
reﬁnement was done using AutoBuster (37) with repeated validation using MolProbity (38). Analyses of
the relevant interfaces were performed using the jsPISA server (39).
Data presentation and statistical analysis. Unless stated otherwise, bars show the arithmetic
means of results from the indicated number of repetitions. Error bars indicate standard errors of the
means (SEM) from the indicated number of individual experiments. Statistical signiﬁcance was calculated
by performing a two-tailed Student t test using Excel. Pearson=s correlation analyses were performed
with GraphPad Prism.
Accession number(s). The atomic coordinates and structure factors for two structures have been
deposited in the Protein Data Bank (http://www.pdb.org/) under accession numbers 6GFB (human BTB)
and 6GFC (rhesus macaque BTB).
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